Tags

Type your tag names separated by a space and hit enter

Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
Prescrire Int. 2009 Oct; 18(103):206.PI

Abstract

Moxifloxacin carries an increased risk of fatal adverse effects and yet is no more effective than other fluoroquinolones. It should simply be taken off the market.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19882787

Citation

"Moxifloxacin: New Indication. Inadequate Restriction of Indications in ENT and Respiratory Infections." Prescrire International, vol. 18, no. 103, 2009, p. 206.
Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire Int. 2009;18(103):206.
(2009). Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire International, 18(103), 206.
Moxifloxacin: New Indication. Inadequate Restriction of Indications in ENT and Respiratory Infections. Prescrire Int. 2009;18(103):206. PubMed PMID: 19882787.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. PY - 2009/11/4/entrez PY - 2009/11/4/pubmed PY - 2009/12/16/medline SP - 206 EP - 206 JF - Prescrire international JO - Prescrire Int VL - 18 IS - 103 N2 - Moxifloxacin carries an increased risk of fatal adverse effects and yet is no more effective than other fluoroquinolones. It should simply be taken off the market. SN - 1167-7422 UR - https://www.unboundmedicine.com/medline/citation/19882787/Moxifloxacin:_new_indication__Inadequate_restriction_of_indications_in_ENT_and_respiratory_infections_ DB - PRIME DP - Unbound Medicine ER -